Import from '@/components'

Leqvio (Inclisiran): How to Safely Stop and What Happens to Your LDL

How Inclisiran Works (and Why Stopping Is Different From Other Drugs)

Inclisiran does not block a receptor or inhibit an enzyme in the usual pharmacological sense. It works further upstream, at the level of gene expression in your liver cells. Understanding this mechanism is the key to understanding what happens when you stop.

The siRNA mechanism in plain language

Inclisiran is a small interfering RNA (siRNA) that targets messenger RNA encoding PCSK9, a protein your liver makes to destroy LDL receptors. When PCSK9 is silenced, your liver keeps more LDL receptors on its surface, clears more LDL-C from your blood, and your circulating LDL-C drops by roughly 50%.

The drug is conjugated to a GalNAc ligand that delivers it specifically to hepatocytes, the liver cells that express the asialoglycoprotein receptor. Once inside the cell, inclisiran loads into the RNA-induced silencing complex (RISC) and causes sequence-specific cleavage of PCSK9 mRNA. RISC is stable inside the cell for months, which is why a twice-yearly injection schedule sustains the LDL-lowering effect. This is also why the offset of effect after stopping is gradual rather than abrupt.

Why this matters for discontinuation

Because inclisiran acts intracellularly and the RISC complex turns over slowly, there is no receptor up-regulation, no rebound hypercholesterolemia above your pre-treatment LDL, and no physical dependence. What does happen is a predictable, time-dependent return of PCSK9 production and a corresponding rise in LDL-C back toward your individual baseline. ORION-10 and ORION-11 pharmacokinetic data show plasma inclisiran is largely undetectable within 48 hours of injection, but the intracellular silencing effect persists for months after the drug clears from plasma.

What the Evidence Says About LDL Rebound After Stopping

The clinical trial program does not include a dedicated arm that randomized participants to discontinuation and measured LDL recovery kinetics in detail. This is an evidence gap worth naming plainly. What the trials do show is the duration of effect from each injection.

ORION-10 and ORION-11 data

In ORION-10 (n = 1,561, predominantly statin-treated patients with ASCVD) and ORION-11 (n = 1,617), inclisiran 284 mg given at Day 1, Day 90, then every six months produced a time-averaged LDL-C reduction of 52.3% in ORION-10 and 49.9% in ORION-11 versus placebo at 510 days. These reductions were measured at trough, the point of minimum drug effect just before the next scheduled dose. The LDL remained suppressed throughout the six-month dosing interval because intrahepatic RISC activity was sustained.

Extrapolating from trough-suppression data: if a dose is simply not given at the six-month mark, LDL-C begins rising from that trough nadir and reaches approximately pre-treatment levels by three to six months after the missed dose, depending on how quickly your liver re-synthesizes PCSK9. Individual variation exists. Women with familial hypercholesterolemia (FH), who have a structural deficit in LDL receptor function, tend to rebound faster and higher than women with polygenic hypercholesterolemia.

What "no rebound above baseline" means clinically

No published evidence suggests inclisiran causes a compensatory overshoot of LDL-C above your pre-treatment baseline. This is physiologically expected: inclisiran reduces PCSK9 but does not alter cholesterol biosynthesis, so when PCSK9 silencing wanes, LDL clearance simply returns to its genetically determined rate. Your cardiovascular risk returns to whatever it was before treatment, not to something worse. Still, a return to a high pre-treatment LDL-C carries the same risk it always did.

Step-by-Step: How to Safely Stop Inclisiran

There is no taper protocol. Inclisiran has no withdrawal syndrome and no pharmacological reason to reduce the dose gradually. A safe discontinuation is primarily a care-coordination process, not a dosing process.

Step 1. Have the conversation before your next injection date

The cleanest time to stop is simply not scheduling the next injection. Because Leqvio is administered in a clinic or pharmacy setting under current prescribing models, you have a natural decision point every six months. If you are within weeks of a scheduled dose and have decided to stop, you can let that appointment lapse without clinical risk.

Step 2. Understand your personal LDL trajectory

Before stopping, ask your prescriber for your pre-treatment LDL-C value and your most recent on-treatment value. The gap between them tells you exactly how much LDL rise to expect. A woman whose LDL was 190 mg/dL before inclisiran and is currently 95 mg/dL on treatment should expect LDL to climb back toward 190 mg/dL over three to six months if no alternative therapy is started.

Step 3. Plan a replacement strategy immediately

The 2019 ACC/AHA guideline on the management of blood cholesterol recommends that high-risk and very-high-risk patients maintain LDL-C below 70 mg/dL and below 55 mg/dL respectively. Stopping inclisiran without a bridge plan means your LDL-C will likely breach these thresholds within three months. Options to discuss with your clinician include:

• Maximally tolerated statin (rosuvastatin 20-40 mg or atorvastatin 40-80 mg)
• Ezetimibe 10 mg added to statin for additional 15-20% reduction
• Bempedoic acid 180 mg for statin-intolerant women
• Evolocumab or alirocumab (monoclonal PCSK9 antibodies) if siRNA intolerance was not the reason for stopping

Step 4. Recheck LDL-C at 3 months

Schedule a fasting lipid panel approximately 12 weeks after your last planned injection. This gives the clearest picture of where your LDL is settling without inclisiran on board.

Step 5. Document the reason for stopping

This matters for insurance and future prescribing. Valid documented reasons include pregnancy planning, cost or access failure, patient preference, injection-site reactions, or a change in overall cardiovascular risk status. Injection-site adverse events occurred in 2.6% of inclisiran-treated patients in ORION-10 and ORION-11, making them the most common drug-related reason to stop.

Pregnancy, Lactation, and Contraception: What Every Woman Needs to Know

This section is required reading if you are of reproductive age, planning a pregnancy, or currently pregnant.

Pregnancy: inclisiran is contraindicated

Inclisiran is classified as contraindicated in pregnancy based on animal reproductive toxicity data. In animal studies, inclisiran caused fetal harm at exposures comparable to clinical doses. No adequate human pregnancy safety data exist. Fetal lipids are essential for neurological development, and agents that substantially alter maternal lipid metabolism carry theoretical teratogenic risk.

If you are pregnant or suspect you may be pregnant, stop inclisiran immediately and contact your prescriber. The six-month dosing interval means you may have received a dose before you knew you were pregnant. Because plasma drug levels fall within 48 hours of injection, ongoing fetal exposure to circulating drug is brief. The intracellular hepatic effect in the mother does not mean fetal tissue is exposed. Even so, stopping is the correct immediate action, and your obstetric team should be informed.

Trying to conceive

Novartis prescribing information recommends discontinuing inclisiran before attempting conception. Because the LDL-lowering effect persists for months after the last injection, your prescriber may advise a washout interval and transition to a pregnancy-compatible lipid-lowering strategy. Bile acid sequestrants such as cholestyramine are currently the preferred lipid-lowering option during pregnancy, though their efficacy is modest compared to inclisiran or statins.

Statins: the contraception context

If you are stopping inclisiran to transition to statin therapy, note that statins are also contraindicated in pregnancy and are FDA Pregnancy Category X. Any woman of reproductive potential taking statins should use reliable contraception and stop statins immediately if pregnancy is confirmed.

Breastfeeding and lactation

No human data exist on the transfer of inclisiran into breast milk. Given the molecular size of the siRNA and its GalNAc conjugate, systemic absorption by a nursing infant is theoretically low, but this has not been studied. The FDA prescribing information advises against use during breastfeeding. If you are breastfeeding and cardiovascular risk management is urgent, discuss the risk-benefit ratio with your clinician on an individual basis.

How Life Stage Changes What Stopping Means for You

Inclisiran is not a drug with one uniform population. The decision to stop, and its consequences, differ meaningfully across a woman's life.

Reproductive years (ages roughly 20-40)

Premenopausal women with heterozygous familial hypercholesterolemia are one of the most common groups to receive inclisiran outside of older age brackets. Approximately 1 in 250 people has heterozygous FH, and many are diagnosed during pregnancy when routine lipid screening occurs. If you are in this group and stopping for pregnancy planning, the cardiovascular stakes are real. Untreated FH during pregnancy carries a meaningful risk of maternal cardiovascular events. Discuss a bridging plan with both your cardiologist and your OB-GYN before stopping.

Perimenopause (ages roughly 45-55)

Perimenopause produces a distinct and underappreciated lipid shift. As estradiol levels fall, LDL-C tends to rise by 10-20 mg/dL independent of diet or body weight. Data from the SWAN (Study of Women's Health Across the Nation) cohort show that LDL-C increases significantly in the two years surrounding the final menstrual period. If you stop inclisiran during perimenopause, you are removing ~50% LDL reduction at the same time your endogenous LDL is climbing. The combined effect can push LDL substantially above your pre-treatment baseline from the perimenopausal hormonal shift alone. This is the life stage in which stopping without an immediate replacement plan carries the highest short-term risk.

A framework for perimenopausal women considering discontinuation:

1. Measure current on-treatment LDL-C
2. Obtain most recent estradiol and FSH to stage menopause transition
3. If FSH is rising and cycles are irregular, assume LDL will drift higher than your pre-inclisiran baseline after stopping
4. Initiate statin or ezetimibe before the next inclisiran dose is due, not after LDL rises

Post-menopause

Post-menopausal women carry the highest absolute ASCVD risk. Cardiovascular disease is the leading cause of death in women over 65, and LDL-C control is one of the few modifiable contributors with strong outcome data. Stopping inclisiran in a post-menopausal woman with established ASCVD without an equivalent lipid-lowering plan in place is a clinical decision that warrants cardiology involvement, not just a primary care conversation.

Who Should and Should Not Stop Inclisiran

Not everyone stopping inclisiran is making the same decision, and not all reasons carry equal clinical weight.

Situations where stopping may be appropriate

• Confirmed pregnancy or imminent conception planning
• Intractable injection-site reactions that have not resolved with technique adjustment
• Cost or insurance failure with no access pathway, while transitioning to an affordable alternative
• Patient has achieved very-low LDL-C (<40 mg/dL) and shared-decision discussion supports a trial off therapy
• New clinical evidence or guideline change alters risk-benefit for the individual

Situations where stopping warrants careful reconsideration

• Established ASCVD (prior MI, stroke, or coronary revascularization) with no replacement plan
• Heterozygous or homozygous familial hypercholesterolemia
• Stopping based on feeling "fine" or "not wanting injections anymore" without lipid monitoring in place
• Perimenopause without an alternative LDL-lowering strategy

The statin-intolerant woman

A meaningful proportion of women who reach inclisiran are there because statins caused myalgia or were otherwise not tolerated. If you are statin-intolerant and stopping inclisiran, your practical alternatives narrow. Bempedoic acid 180 mg reduced LDL-C by approximately 21% in statin-intolerant patients in the CLEAR Outcomes trial. Ezetimibe 10 mg alone provides roughly 15-20% additional reduction. These are meaningful but not equivalent to inclisiran's ~50% effect. Your LDL will rise; the question is how far and whether an alternative drug combination keeps it within your target range.

Sex-Specific Data and Evidence Gaps

Women are not proportionally represented in many cardiovascular outcomes trials, and inclisiran is no exception. In ORION-10, women made up approximately 28% of enrolled participants. In ORION-11, women comprised roughly 33%. The LDL-lowering magnitude appeared consistent across sexes in subgroup analyses, but these analyses were not powered to detect sex-specific differences in cardiovascular outcomes.

What is not yet known for women specifically:

• Whether the duration of intrahepatic RISC activity differs by sex or hormonal status
• Whether perimenopausal hormonal flux alters inclisiran's pharmacokinetics or hepatocyte uptake via the GalNAc-asialoglycoprotein receptor pathway
• How the LDL rebound curve differs between premenopausal and post-menopausal women
• Long-term safety data in women under 40 with FH who require decades of therapy

These are genuine gaps, not minor footnotes. Any clinical decision about stopping inclisiran in a woman should account for this uncertainty rather than assuming trial results in a predominantly older, male population map directly onto her biology.

Practical Monitoring After Stopping

Once you and your clinician agree to stop inclisiran, this monitoring schedule is reasonable based on the pharmacokinetic offset profile:

| Timepoint | Action | |---|---| | Day of last injection | Confirm replacement therapy plan in writing | | Week 4 | Optional LDL-C check if baseline was very high (>250 mg/dL) | | Week 12 | Fasting lipid panel. This is the most important post-discontinuation check | | Week 24 | Repeat lipid panel to confirm LDL has stabilized on new regimen | | 12 months | Annual lipid monitoring thereafter |

If the Week 12 LDL-C is above your individualized target, escalate therapy at that visit rather than waiting for the annual check. Cardiovascular risk accumulates with LDL-C exposure over time, and a three-month window of uncontrolled LDL in a high-risk woman is not trivial.

A Note on Cost, Access, and Restarting

One common reason women stop inclisiran is cost. The list price in the United States exceeds $3,000 per injection without insurance coverage, and prior authorization requirements are substantial. If you are stopping for financial reasons rather than clinical ones, ask your prescriber about the Novartis patient support program before your next dose lapses. Restarting inclisiran after a gap does not require a specific re-loading protocol according to published prescribing information, but it does restart the Day 1, Day 90, then every-six-months schedule from the point of re-initiation.